Iodine Supplementation in Graves' Hyperthyroidism

Inclusion criteria

• patients newly diagnosed with Graves' hyperthyroidism and not treated; or
• patients diagnosed with Graves' hyperthyroidism and treated with ATDs regularly less than 3 months, serum TSH is measured below normal reference range, serum FT3 or FT4 or both are measured above normal reference range and serum TRAb is positive; or
• patients diagnosed with Graves' hyperthyroidism and not regularly treated with ATDs more than 3 months, serum TSH is measured below normal reference range, serum FT3 or FT4 or both are measured above normal reference range and serum TRAb is positive.

Exclusion criteria

• thyroid enlargement of grade 3;
• serum TRAb is measured above 40IU/L;
• moderate or severe thyroid-associated eye diseases;
• hepatic disease history including chronic active hepatitis, severe hepatic dysfunction, liver cirrhosis, etc., and serum transaminase level is 3 times higher than the upper normal limit and/or total bilirubin level is higher than 34.2μmol/L with hepatic protective drugs;
• history of moderate-to-severe or end-stage renal disease: eGFR<60mL/min/1.73m2 with simplified MDRD formula;
• serum WBC<3.0×109／L or neutrophil count<1.5×109／L;
• history of severe cardiocerebrovascular disease, digestive disease, hematopoietic system disease, other autoimmune diseases in addition to Graves' hyperthyroidism, tumors, psychosis, etc.;
• blood pressure>180/100mmHg with regular antihypertensive drugs treatment;
• severe comorbidities and complications of hyperthyroidism with ATDs treatment;
• history of multiple drug allergies;
• a family planning plan in 3 years.